61877-83-6

Upstream product

• 75-64-9 tert-butylamine 
• 53732-26-6 1,2-epoxy-3-[2-chloro-5-methylphenoxy]propane 
• 615-74-7 2-chloro-5-methylphenol 
• 15148-80-8 bupranolol hydrochloride 
• 106-89-8 epichlorohydrin 

Downstream Products

• 125721-14-4 3-(2-Chloro-5-methyl-phenoxy)-2-[(Z)-hydroxyimino]-propionaldehyde oxime 
• 125721-05-3 3-(2-Chloro-5-methyl-phenoxy)-2-[(E)-hydroxyimino]-propionaldehyde oxime 
• 125720-93-6 1-tert-Butylamino-3-(2-chloro-5-methyl-phenoxy)-propan-2-one oxime 
• 125720-83-4 1-tert-Butylamino-3-(2-chloro-5-methyl-phenoxy)-propan-2-one oxime 
• 15148-80-8 rac-bupranolol hydrochloride 
• 15148-80-8 (S)-bupranolol hydrochloride 
• 15148-80-8 (R)-bupranolol hydrochloride 

Relevant academic research and scientific papers

Synthesis, phase behavior and absolute configuration of β-adrenoblocker bupranolol and related compounds

β-Blocker bupranolol 1, it's hydrochloride and their precursors 1-(2-chloro-5-methylphenoxy)-2,3-epoxypropane 2 and 3-(2-chloro-5-methylphenoxy)propane-1,2-diol 3 were prepared in racemic and single-enantiomer forms. For all the studied compounds phase behavior during crystallization was established on the basis of IR, DSC and X-ray investigations. Absolute configurations were established for compounds 1 and 2. Being conglomerate, racemic oxirane 2 was resolved by direct entrainment procedure. Being anticonglomerate, in the process of recrystallization, almost enantiopure 1·HCl accumulates in the mother liquor, not in the crystalline precipitate.

Effect of basic and acidic additives on the separation of some basic drug enantiomers on polysaccharide-based chiral columns with acetonitrile as mobile phase

The separation of enantiomers of 16 basic drugs was studied using polysaccharide-based chiral selectors and acetonitrile as mobile phase with emphasis on the role of basic and acidic additives on the separation and elution order of enantiomers. Out of the studied chiral selectors, amylose phenylcarbamate-based ones more often showed a chiral recognition ability compared to cellulose phenylcarbamate derivatives. An interesting effect was observed with formic acid as additive on enantiomer resolution and enantiomer elution order for some basic drugs. Thus, for instance, the enantioseparation of several β-blockers (atenolol, sotalol, toliprolol) improved not only by the addition of a more conventional basic additive to the mobile phase, but also by the addition of an acidic additive. Moreover, an opposite elution order of enantiomers was observed depending on the nature of the additive (basic or acidic) in the mobile phase.

Continuous and convergent access to vicinyl amino alcohols

Five active pharmaceutical ingredients (APIs) containing the vicinyl amino alcohol moiety were synthesized using a convergent chemical assembly system. The continuous system is composed of four flow reaction modules: biphasic oxidation, Corey-Chaykovsky epoxidation, phenol alkylation, and epoxide aminolysis. Judicious choice of reagents and module order allowed for two classes of β-amino alcohols, aryl and aryloxy, to be synthesized in good (27-69%) overall yields.

THERAPY FOR COMPLICATIONS OF DIABETES

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.

ANTIHYPERTENSIVE THERAPY

A new use of darusentan is provided in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs. The composition comprises darusentan in an amount providing a therapeutically effective daily dose; wherein (a) the composition is orally deliverable and/or (b) the daily dose of darusentan is effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures. Further provided is a new use of darusentan in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy, wherein the composition is administered adjunctively with at least one diuretic and at least one antihypertensive drug selected from ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers.

Method for treating resistant hypertension

A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers. The darusentan is orally administered at a dose and frequency effective, in combination with the baseline regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.

Enteric coated mixture of 4-(2-hydroxy-3-isopropylamino-propoxy) indole and sodium lauryl sulphate

The present invention provides a pharmaceutical composition for controlled release of 4-(2-hydroxy-3-isopropylamino-propoxy) indole in the intestinal tract, admixed with sodium lauryl sulphate, and enteric coated.